A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

PHASE3CompletedINTERVENTIONAL
Enrollment

579

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

April 20, 2023

Study Completion Date

May 12, 2023

Conditions
ObesityOverweight
Interventions
DRUG

Tirzepatide

Administered SC

OTHER

Placebo

Administered SC

Trial Locations (65)

1056

Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aire

1405

Instituto Médico Especializado (IME), Buenos Aires

1430

Glenny Corp, Buenos Aires

4200

Sanatorio Norte, Santiago del Estero

14609

Rochester Clinical Research, Inc., Rochester

15243

Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh

19104

Penn Medicine: University of Pennsylvania Health System, Philadelphia

19446

Detweiler Family Medicine & Associates, Lansdale

23606

Health Research of Hampton Roads, Inc., Newport News

27157

Wake Forest University Baptist Medical Center (WFUBMC), Winston-Salem

27408

PharmQuest, Greensboro

27514

University of North Carolina Medical Center, Chapel Hill

29607

Tribe Clinical Research, LLC, Greenville

33134

Clinical Research of South Florida, Coral Gables

33165

New Horizon Research Center, Miami

33351

Precision Clinical Research, Sunrise

33401

Metabolic Research Institute, Inc., West Palm Beach

33606

Clinical Research of West Florida, Tampa

37204

Vanderbilt Health One Hundred Oaks, Nashville

37620

Holston Medical Group, Bristol

39532

The National Diabetes & Obesity Research Institute, Biloxi

44122

Cleveland Clinic Foundation, Cleveland

46123

American Health Network of IN, LLC, Avon

46131

American Health Network of IN, LLC, Franklin

47304

American Health Network of IN, LLC, Muncie

60201

Evanston Premier Healthcare Research LLC, Evanston

65810

Clinvest Research LLC, Springfield

66606

Cotton O'Neil Mulvane, Topeka

68114

Quality Clinical Research, Omaha

70072

Tandem Clinical Research,LLC, Marrero

73069

Intend Research, LLC, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Dallas Diabetes Research Center, Dallas

77040

Juno Research, Houston

78231

Consano Clinical Research, LLC, Shavano Park

78681

Texas Diabetes & Endocrinology, P.A., Round Rock

83221

Elite Clinical Trials, Blackfoot

83440

Elite Clinical Trials, Rexburg

83646

Solaris Clinical Research, Meridian

89148

Palm Research Center Sunset, Las Vegas

90057

National Research Institute - Wilshire, Los Angeles

90255

National Research Institute - Huntington Park, Huntington Park

91763

Catalina Research Institute, LLC, Montclair

91978

Encompass Clinical Research, Spring Valley

92704

National Research Institute (NRI) - Santa Ana, Santa Ana

94598

Diablo Clinical Research, Inc., Walnut Creek

97210

Summit Research Network, Portland

98405

MultiCare Institute for Research & Innovation, Tacoma

29055450

CEDOES, Vitória

06708

Chase Medical Research, LLC, Waterbury

C1120AAC

Centro Médico Viamonte, CABA

C1179AAB

Investigaciones Medicas Imoba Srl, CABA

C1204AAD

Instituto Centenario, CABA

C1023AAB

Stat Research S.A., Ciudad Autónoma de Buenos Aire

C1205AAO

CEMEDIAB, C.a.b.a.

80030-480

Cline Research Center, Curitiba

80040-110

Quanta Diagnóstico e Terapia, Curitiba

01228-200

CPCLIN, São Paulo

03325-050

BR Trials - Ensaios Clinicos e Consultoria, São Paulo

22241-180

IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro

01228-000

CPQuali Pesquisa Clínica, São Paulo

04266-010

CEPIC - Centro Paulista de Investigação Clínica, São Paulo

00961

Advanced Clinical Research, LLC, Bayamón

00674

Manati Center for Clinical Research, Manatí

00716

Ponce Medical School Foundation Inc., Ponce

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04657016 - A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Biotech Hunter | Biotech Hunter